BioPhorum Extractables Test Report and Reference File Download Link
https://eu2.contabostorage.com/00f3241116844f24b628f46d81abb929:st1/folder6/6615/1656154620_bpog_extractables_test_report_template__jan2019_1_-_Standar_Format.xlsx
2026-05-30 07:28:04 - Admin
<style> body{ font-family: Arial, Helvetica, sans-serif; line-height: 1.6; margin:0; padding:0 1rem; color:#333; background:#fafafa; } header{ background:#004e89; color:#fff; padding:1rem 0; text-align:center; } main{ max-width:800px; margin:2rem auto; } h1,h2,h3{ color:#004e89; } table{ width:100%; border-collapse:collapse; margin:1rem 0; } th, td{ border:1px solid #ddd; padding:0.5rem; text-align:left; } th{ background:#e2f0fb; } ul{ margin:0 0 1rem 1.5rem; } a{ color:#004e89; } </style><header> <h1>BioPhorum Extractables Test Report An Overview</h1></header><main> <section> <h2>What Are Extractables?</h2> <p> Extractables are chemical substances that migrate from a material or component when it is exposed to a solvent under exaggerated conditions (elevated temperature, aggressive solvent, prolonged contact). They represent the worstcase chemical profile of a product in contact with the material and are the basis for safety assessment of pharmaceuticals, biologics, and medical devices. </p> </section> <section> <h2>Why the BioPhorum Extractables Test?</h2> <p> The BioPhorum Extractables Working Group (BEWG) was created to harmonise testing approaches across the biopharma industry. Its test protocol sets out a common set of solvents, temperatures, and times, allowing companies to compare results, share data, and build a robust extractables database. </p> <p> Benefits of using the BioPhorum protocol include: </p> <ul> <li>Standardised methodology reduces variability between suppliers.</li> <li>Regulatory alignment many agencies recognise the BEWG approach.</li> <li>Riskbased decision making helps prioritize leachables testing.</li> <li>Accelerated material qualification data can be leveraged across programmes.</li> </ul> </section> <section> <h2>Core Elements of the Test</h2> <h3>Materials and Components</h3> <p> The protocol applies to containers, closures, tubing, filters, and any polymerbased component that will be in direct contact with drug product or process intermediates. </p> <h3>Solvent Selection</h3> <p>The following solvents are recommended, each representing a different polarity range:</p> <table> <thead> <tr><th>Solvent</th><th>Polarity</th><th>Typical Use</th></tr> </thead> <tbody> <tr><td>Water (USP)</td><td>Very polar</td><td>Most biologics, aqueous processes</td></tr> <tr><td>20% Ethanol in water</td><td>Polar</td><td>Protein formulations, buffer systems</td></tr> <tr><td>100% Ethanol</td><td>Mediumpolar</td><td>Vaccines, smallmolecule APIs</td></tr> <tr><td>Isopropanol</td><td>Mediumpolar</td><td>Cleaning validation</td></tr> <tr><td>Acetone</td><td>Lowpolar</td><td>Organic extracts, nonaqueous processes</td></tr> <tr><td>Hexane</td><td>Nonpolar</td><td>Lipidbased products, oils</td></tr> </tbody> </table> <h3>Test Conditions</h3> <ul> <li><strong>Temperature:</strong> 40C for waterbased solvents; 50C for organic solvents.</li> <li><strong>Duration:</strong> 72hours (minimum) to achieve equilibrium.</li> <li><strong>SurfacetoVolume Ratio:</strong> 1cm of material per 5mL of solvent (or as specified for the component).</li> </ul> <h3>Analytical Techniques</h3> <p> A typical BEWG report combines several orthogonal methods to capture a broad chemical space: </p> <ul> <li>GCMS (Gas Chromatography Mass Spectrometry) for volatile and semivolatile organics.</li> <li>LCMS/MS (Liquid Chromatography Tandem MS) for nonvolatile, polar, and highmolecularweight compounds.</li> <li>GCFID (Flame Ionisation Detector) for quantifying total organic carbon.</li> <li>ICPMS (Inductively Coupled Plasma MS) for elemental leachables (e.g., metals, halides).</li> <li>NMR (Nuclear Magnetic Resonance) for structural elucidation of unknowns.</li> </ul> </section> <section> <h2>Structure of a BioPhorum Extractables Report</h2> <p>A typical report contains the following sections:</p> <ol> <li><strong>Executive Summary</strong> concise overview of findings and risk implications.</li> <li><strong>Scope & Materials</strong> description of the component, manufacturing lot, and test matrix.</li> <li><strong>Methodology</strong> detailed test conditions, solvent list, and analytical parameters.</li> <li><strong>Results</strong> <ul> <li>Tabulated concentration data (g/g or ppm) for each identified compound.</li> <li>Peakarea charts and representative chromatograms.</li> <li>Identification confidence levels (e.g., confirmed, probable, tentative).</li> </ul> </li> <li><strong>Discussion</strong> interpretation of results, comparison with historical data, and assessment of potential leachable risk.</li> <li><strong>Conclusions & Recommendations</strong> whether the material is suitable, need for additional leachables testing, or mitigation actions (e.g., preconditioning).</li> <li><strong>Appendices</strong> raw data files, detailed instrument settings, and reference standards used.</li> </ol> </section> <section> <h2>Interpreting the Data</h2> <p> Not every extractable is automatically a safety concern. The following framework helps determine relevance: </p> <ul> <li><strong>Concentration Thresholds</strong> compare against the ICH Q3D limits for elemental impurities and the USP<em>Impurities</em> limits for organic compounds.</li> <li><strong>Toxicological Evaluation</strong> use available safety data (e.g., TOXNET, ECHA) to assess carcinogenicity, genotoxicity, or organ toxicity.</li> <li><strong>Process Relevance</strong> if the solvent used in the extractables test is not part of the intended manufacturing process, exposure may be lower.</li> <li><strong>Potential for Leaching</strong> compounds that are highly volatile or soluble in the actual product medium pose higher leachable risk.</li> </ul> </section> <section> <h2>Benefits of a Shared Database</h2> <p> By contributing data to the BioPhorum Extractables Database, companies gain: </p> <ul> <li>Benchmarking against peergenerated extractables profiles.</li> <li>Reduced need for duplicate testing on common materials.</li> <li>Faster regulatory submissions reviewers can reference alreadypublished data.</li> </ul> <p> Participation is voluntary, but the industry trend is moving toward open data exchange to improve overall product safety and accelerate development timelines. </p> </section> <section> <h2>Key Takeaways</h2> <ul> <li>The BioPhorum extractables protocol provides a consistent, riskfocused approach for evaluating material compatibility with biopharmaceutical products.</li> <li>Standardised solvents, temperatures, and analytical methods make results comparable across suppliers.</li> <li>Interpretation requires a blend of quantitative thresholds, toxicological insight, and knowledge of the actual product formulation.</li> <li>Sharing results in the BEWG database amplifies the value of each test, helping the whole industry achieve safer, faster product launches.</li> </ul> </section> <section> <h2>Further Reading & Resources</h2> <ul> <li><a href="https://www.biophorum.com/extractables-working-group" target="_blank">BioPhorum Extractables Working Group Official Site</a></li> <li>ICH Q3D(R1) Guidance on Elemental Impurities</li> <li>USP <em>General Chapter <sup>212</sup> Impurities</em></li> <li>FDA Guidance: <em>Drug Products Content and Purity</em></li> </ul> </section></main>```